Welcome to Helix Talk, a podcast presented by the Rosalind Franklin University College of Pharmacy.

We're hoping that our real-life clinical pearls and discussions will help you stay up to date

and improve your pharmacy knowledge. This podcast contains general information for educational purposes only. This is not

professional advice and should not be used in lieu of obtaining advice from a qualified health care

provider. And now, on to the show. Welcome to episode 31 of Helix Talk. I'm your co-host, Dr.

Kaine. I'm Dr. Schumann. And I'm Dr. Patel. And today we have the

dream team back. Dr. Patel was gone on vacation. Congratulations again on your wedding and honeymoon.

Thank you. And Dr. Schumann, we spoke last episode, but it's good to have you back from Honduras.

Yep, right again, ready to get back. The three of us in that kind of consistency for a few weeks to get really nailing down some good subjects again.

I too. I'm excited.

Great. So today's episode, we're going to kind of finalize what we've been talking about the last two episodes, which is therapeutic drug monitoring of kind of clinically relevant common medications that pharmacists play an important role in.

So just to recap, the first episode we talked about phenyton or dilanton and warfarin or

kumidin. The second episode we talked about belprote, depokine, depacan, and dejoxin, or

lenoxin. And today we're talking about with Dr. Rital, oral tecrolomis, and

with Dr. Schumann, we're going to be talking about lithium. So Dr. Patel, would you like to

kind of kick us off with your drug of choice today? Sure, thanks. So we're going to be talking

about how do we monitor and what goes with the whole oral tachrylamis therapy.

Brand name is program.

As we all know, it's an immunospressant.

And in particular, it's a calcium urine inhibitor, which is used as an anti-rejection agent

along with some other agents too and various different transplant patients.

So basically, the mechanism of action is dampening down the T-cell cell activity

...